Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 16/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 15/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4916998 | 1.00 | CCR5 (0.36) | CCR5ITGALITGB2ICAM1S1PR1 | |
| SCHEMBL4637350 | 1.00 | CCR5 (0.36) | CCR5ITGALITGB2ICAM1S1PR1 | |
| SCHEMBL4905498 | 0.90 | S1PR1 (0.31) | S1PR1S1PR5 | |
| SCHEMBL4905490 | 0.90 | S1PR1 (0.31) | S1PR1S1PR5 | |
| SCHEMBL4909886 | 0.89 | ITGAL (0.36) | CCR5ITGALITGB2ICAM1S1PR1 | |
| SCHEMBL4637415 | 0.89 | ITGAL (0.36) | CCR5ITGALITGB2ICAM1S1PR1 | |
| SCHEMBL4637419 | 0.89 | ITGAL (0.36) | CCR5ITGALITGB2ICAM1S1PR1 | |
| SCHEMBL4639084 | 0.89 | MCHR1 (0.36) | ITGALITGB2ICAM1 | |
| SCHEMBL4637464 | 0.89 | MCHR1 (0.36) | ITGALITGB2ICAM1 | |
| SCHEMBL4637461 | 0.89 | MCHR1 (0.36) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | BAUMANN KARL | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | VCAM1, ICAM1, EPCAM | CCR5 73/4885ITGAL 15/4885ITGB2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.